Abstract:There is continuing assessment to find the most effective management strategy for primary soft tissue sarcomas. The goal of treatment for any patient with malignant neoplasm is to provide a tumour-free survival without clinically appreciable treatment-related morbidity. For most adult patients, this currently is attempted by a combination of relatively conservative surgery and moderate dose of radiation. The concept being that radiation at dose levels of 50 to 60 Gy is adequate to inactivate the tumour cells which lie beyond the margins of a conservative resection, i.e., it replaces the resection of large volumes of normal tissue. Laboratory measurements of radiation sensitivity of cell lines derived from sarcomas of soft tissue tumours have shown that they are not radiation-resistant relative to the cell lines derived form epithelial tumours. Hence, there is no surprise the this combined modality approach has been demonstrated to be effective. The frequency of local control (85% to 90%) is at least as high as that combined by ablative surgery, but with much lesser decrement in functional and cosmetic status. Additionally, radiation at dose levels of about 75 Gy is effective in achieving worthwhile local control rates when administered against small sarcomas of the soft tissues, e.g. volumes of < or = 60 ml. Thus, for selected tumours, radiation alone does offer a reasonable option when surgery is not feasible for technical reasons or the patient is not operable for medical reasons. Available data do not indicate a clear advantage for adjuvant chemotherapy for this group of tumours. Trials are in progress to assess the efficacy of neo-adjuvant chemotherapy. We are conducting a phase II trial of MAID chemotherapy and radiation preoperatively; the results to date are superior to matched concurrently treated patients. For local therapy, high and approximately comparable local control rates are being reported for several approaches: radical compartmental resection for selected patients, surgery and postoperative radiation therapy, surgery and preoperative radiation treatment, resection and intraoperative placement of catheters for brachytherapy and intra-arterial adriamycin, radiation and resection. Our preferred approach for T 2, grades II-III sarcomas of the soft tissues is radiation prior to surgery. There are, however, no data on the functional and cosmetic status after treatment of patients whose sarcomas are of a specified site and volume for treatment by these diverse methods. This is a critically important question in the assessment of proper clinical role of each of these approaches.

Chemotheraphy for soft tissue sarcomas

Chemotherapeutic drugs for soft tissue sarcomas: a review

Adjuvant high dose rate brachytherapy in soft tissue sarcoma: a report of 11cases

Advances in the targeted therapy of liposarcoma.

Advances of Systemic Treatment for Adult Soft-Tissue Sarcoma

Advances in therapy of sarcoma of soft tissue

Diagnosis and treatment of soft tissue sarcomas:hot and difficult problems

Advances in molecular targeted therapy for soft tissue sarcomas

Preoperative sequential chemotherapy and hypofractionated radiotherapy combined with comprehensive surgical resection for high-risk soft tissue sarcomas: a retrospective study

Observe the recent curative effect of postoperative radiotherapy in soft tissue sarcoma

Heterogeneity of Soft Tissue Sarcomas and Its Implications in Targeted Therapy

Intraarterial Chemotherapy Plus Surgery in Patients with Extremity Soft Tissue Sarcoma

Intra-arterial Chemotherapy and Limb-Salvage in Patients with Soft Tissue Sarcoma

Chemo-senolytic therapeutic potential against angiosarcoma

Clinical Analysis of 251 Cases of Soft Tissue Sarcomas

Liposarcoma and Its Treatment

A Retrospective Clinical Study of the Efficacy of Chemotherapy Combined with Adjuvant Radiation Therapy in the Treatment of AJCC Stage II or Stage III Soft Tissue Sarcoma of the Extremity after Wide Excision

Soft tissue sarcomas: radiation as a therapeutic option

[Experience and Discussion on Treatment of High-Grade Soft Tissue Sarcomas of Crura in Youth].

Combined Chemotherapy And I-125-Particle Implantation For Treatment Of Children With Head And Neck Soft Tissue Sarcomas Improve The Short-Term Efficacy: Beijing Children'S Hospital Experience Over 2 Years

PET/CT and PET/MR in Soft Tissue Sarcoma: An Update